Osteoporosis drug to be trialled for COVID-19

Supercomputer screening identified the compound as a potential treatment

Italy's medicines regulator has given the go-ahead for human clinical trials on raloxifene, a generic osteoporosis drug that researchers hope may help reduce COVID-19 symptoms and make patients less infectious.

Coronavirus particles

The drug was identified as a potential COVID-19 treatment by the use of supercomputers to screen more than 400,000 molecules for chemical characteristics that might inhibit the virus, focusing on those already approved for use in humans.

Andrea Beccari, from Exscalate4Cov, a public-private consortium led by Italy